Skip to Content
Merck
All Photos(1)

Documents

A9522

Sigma-Aldrich

Anti-Antithrombin III antibody produced in rabbit

fractionated antiserum, lyophilized powder

Synonym(s):

Anti-AT3

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
12352203
NACRES:
NA.41

biological source

rabbit

Quality Level

conjugate

unconjugated

antibody form

fractionated antiserum

antibody product type

primary antibodies

clone

polyclonal

form

lyophilized powder

species reactivity

human

packaging

vial of 2 mL lyophilized antiserum

technique(s)

indirect ELISA: 1:25,000

UniProt accession no.

storage temp.

2-8°C

target post-translational modification

unmodified

Gene Information

human ... SERPINC1(462)

General description

Antithrombin III (ATIII) is a small glycoprotein produced by the liver that functions as a serine protease inhibitor to block coagulation.
Antithrombin III is a 58kDa glycoprotein synthesized in the liver. It has two domains, a heparin-binding domain and target protease binding domain.

Immunogen

human antithrombin III

Application

Anti-Antithrombin III antibody has been used in western blotting and antigenic assay.

Biochem/physiol Actions

Antithrombin III is a serine protease inhibitor which affects many intrinsic and extrinsic blood coagulation pathways. It inactivates the function of thrombin and factor X in blood. Severe sepsis is caused due to lack of antithrombin III.

Physical form

Lyophilized from 0.01 M phosphate buffered saline, pH 7.2

Reconstitution

Reconstitute with 2 mL deionized water.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Pictograms

Corrosion

Signal Word

Danger

Hazard Statements

Precautionary Statements

Hazard Classifications

Eye Dam. 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Maria Eugenia de la Morena-Barrio et al.
Blood, 140(2), 140-151 (2022-04-30)
Antithrombin deficiency, the most severe congenital thrombophilia, might be underestimated, as some pathogenic variants are not detected by routine functional methods. We have identified 2 new SERPINC1 variants, p.Glu227Lys and p.Asn224His, in 4 unrelated thrombophilic patients with early and recurrent
High-dose antithrombin III in severe sepsis: a randomized controlled trial
Warren B L, et al.
JAMA : The Journal of the American Medical Association, 286(15), 1869-1878 (2001)
Sean P Harrison et al.
Experimental & molecular medicine, 55(9), 2005-2024 (2023-09-01)
The lack of physiological parity between 2D cell culture and in vivo culture has led to the development of more organotypic models, such as organoids. Organoid models have been developed for a number of tissues, including the liver. Current organoid
Carlos Bravo-Pérez et al.
American journal of hematology, 97(2), 216-225 (2021-11-21)
Antithrombin deficiency, the most severe thrombophilia, might be underestimated, since it is only investigated in cases with consistent functional deficiency or family history. We have analyzed 444 consecutive, unrelated cases, from 1998 to 2021, with functional results supporting antithrombin deficiency
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
Weitz J I, et al.
The Journal of Clinical Investigation, 86(2), 385-391 (1990)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service